Meridian Bioscience (VIVO) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $2.36 -9.23%
Financial Fact:
EFFECT OF DILUTIVE STOCK OPTIONS: -756K
Today's EPS Names:
OPY, BNCC, ZVOI, More
Financial Fact:
EFFECT OF DILUTIVE STOCK OPTIONS: -756K
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Meridian Bioscience (Nasdaq: VIVO) reported Q4 EPS of $0.19, in-line with the analyst estimate of $0.19. Revenue for the quarter came in at $48 million versus the consensus estimate of $46.2 million.
Meridian Bioscience reaffirmed FY2015 guidance.
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kosmos Energy (KOS) Misses Q3 EPS by 3c
- Morgan Stanley Upgrades Delhivery Ltd (DELHIVER:IN) to Overweight
- Elbit Systems wins $170M IDF artillery training center contract
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
